nā koho lapaʻau metastatic prostate cancer

ʻO ka maʻi maʻi prostate metastatic ʻo ia ka maʻi maʻi prostate i laha ma waho o ka gland prostate i nā wahi ʻē aʻe o ke kino. ʻOkoʻa nā koho lapaʻau ma muli o ka nui o ka laha ʻana, nā lāʻau lapaʻau mua, a me ke olakino holoʻokoʻa o ka mea maʻi. ʻO nā lāʻau lapaʻau maʻamau ka hormone therapy, chemotherapy, immunotherapy, a me radiation therapy. Hoʻohana nui ʻia nā lāʻau lapaʻau hou e like me radiopharmaceuticals a me PARP inhibitors. Hoʻolaʻa ʻia ʻo Shandong Baofa Cancer Research Institute i ka hāʻawi ʻana i nā noiʻi ʻokiʻoki a me nā koho lapaʻau e hoʻomaikaʻi i nā hopena o ka maʻi. ka maʻi ʻaʻai prostate metastatic i ka wā e laha ai mai ka prostate gland a i nā wahi ʻē aʻe, ʻo ka mea maʻamau i nā iwi, nā ʻōpū lymph, nā ate, a me nā māmā. He mea koʻikoʻi ka hoʻomaopopo ʻana i ka pae a me ka pae o ka maʻi kanesa e hoʻoholo ai i ka hana maikaʻi loa. ʻO ka maʻi maʻamau e pili ana i nā hoʻokolohua kiʻi e like me ka scan iwi, CT scans, a me MRI, me nā biopsies.He aha ka mea e hana ai i ka maʻi maʻi prostate metastatic? Hiki i kekahi mau hoʻololi genetic a me nā mea pili i ka microenvironment tumor ke kōkua i kēia kaʻina hana. ʻO ka helu Gleason a me ka loaʻa ʻana o nā biomarkers kikoʻī he mea koʻikoʻi hoʻi i ka wānana ʻana i ka pilikia o ka metastasis. Nā Koho Lapaʻau Maʻamau no ka Metastatic Prostate Cancer. ka maʻi ʻaʻai prostate metastatic. Hoʻohana pinepine ʻia kēia mau mea i ka hui pū ʻana a i ʻole ka sequentially no ka hoʻonui ʻana i ka pono. ʻO ka Hormone Therapy (Androgen Deprivation Therapy - ADT) Hormone therapy, i ʻike ʻia ʻo androgen deprivation therapy (ADT), manaʻo e hoʻohaʻahaʻa i ke kiʻekiʻe o nā hormones kāne (androgens) i loko o ke kino, kahi e hoʻoulu ai i ka ulu ʻana o nā maʻi maʻi prostate. Hiki ke hoʻokō ʻia kēia ma o ka hoʻoheheʻe ʻana (orchiectomy) a i ʻole ka lāʻau lapaʻau me ka hoʻohana ʻana i nā agonists LHRH a i ʻole antagonists. ʻO nā hopena ʻaoʻao maʻamau e pili ana i ka wela wela, nalowale o ka libido, erectile dysfunction, a me ka luhi. ʻO ka ADT ka lāʻau lapaʻau mua no ka maʻi ʻaʻai prostate metastatic.ChemotherapyHoʻohana ʻia ka hoʻohana ʻana i nā lāʻau lapaʻau e pepehi ai i nā maʻi kanesa. Hoʻohana pinepine ʻia i ka wā ʻaʻole maikaʻi ka hormone therapy (castration-resistant prostate cancer - CRPC). ʻO nā lāʻau lapaʻau chemotherapy maʻamau i hoʻohana ʻia no ka maʻi maʻi prostate e komo pū me docetaxel a me cabazitaxel. Hiki i nā hopena ʻaoʻao ke komo i ka nausea, ka luaʻi ʻana, ka lauoho lauoho, ka luhi, a me ka piʻi ʻana o ka maʻi. Hoʻoikaika ʻo Shandong Baofa Cancer Research Institute i ka mālama ʻana i nā hopena ʻaoʻao e hoʻomaikaʻi i ka maikaʻi o ke ola. Hiki ke hoʻohana ʻia no ka mālama ʻana i ka prostate gland ponoʻī (external beam radiation therapy or brachytherapy) a i ʻole ke kuhikuhi ʻana i nā wahi metastatic i loko o nā iwi (external beam radiation therapy). Hiki i ka lāʻau lapaʻau ke kōkua i ka hoʻēmi ʻana i ka ʻeha a hoʻomaikaʻi i ka maikaʻi o ke ola. ʻO nā hopena ʻaoʻao e pili ana i ka wahi i mālama ʻia akā hiki ke komo i ka luhi, ka ʻili ʻili, a me nā pilikia o ka ʻōpū. ka maʻi ʻaʻai prostate metastatic. Eia nō naʻe, hiki ke noʻonoʻo ʻia i nā kūlana kikoʻī, e like me ka wehe ʻana i ka maʻi maʻi mua e hoʻēmi i nā hōʻailona a i ʻole i hui pū ʻia me nā lāʻau lapaʻau ʻē aʻe. Kakaʻikahi ka hana ʻana i ka wehe ʻana i nā ʻeha metastatic. Nā Hana Hou a me ka Emerging Treatments. nā koho lapaʻau metastatic prostate cancer e ulu mau ana, e hāʻawi ana i ka manaʻolana no nā hopena maikaʻi a me ka maikaʻi o ke ola. Eia kekahi o nā ala hou: Radiopharmaceuticals ʻO Radiopharmaceuticals nā lāʻau lapaʻau e hāʻawi pololei i ka radiation i nā maʻi kanesa. ʻO Radium-223 dichloride (Xofigo) kahi radiopharmaceutical i hoʻohana ʻia e mālama i nā metastases iwi i nā maʻi me CRPC. ʻO Lutetium-177 PSMA-617 kekahi radiopharmaceutical e kuhikuhi ana i ka prostate-specific membrane antigen (PSMA), he protein i loaʻa ma ka ʻili o nā maʻi maʻi prostate. Hiki i nā hopena ʻaoʻao ke hoʻopili i ka hoʻopau ʻana i ka iwi o ka iwi a me ka luhi. ʻO Sipuleucel-T (Provenge) kahi lapaʻau immunotherapy i ʻae ʻia no ka CRPC asymptomatic a i ʻole ka hōʻailona liʻiliʻi. Hoʻopili ia i ka hōʻiliʻili ʻana i nā cell immune o ka mea maʻi, hoʻololi iā lākou e ʻike i nā sela maʻi prostate, a laila hoʻokomo hou iā lākou i loko o ka mea maʻi. ʻO Pembrolizumab, kahi mea hoʻopaʻa hoʻopaʻa, he koho ia no nā poʻe maʻi me nā hoʻololi genetic kikoʻī a i ʻole microsatellite instability kiʻekiʻe (MSI-H). Hiki ke hana maikaʻi kēia mau lāʻau lapaʻau i nā maʻi me kekahi mau hoʻololi genetic, e like me BRCA1/2 mutations. ʻO Olaparib a me rucaparib nā mea hoʻopiʻi PARP i'āponoʻia no ka mālamaʻana i ka CRPC. ʻO nā hopena ʻaoʻao maʻamau ka anemia, ka luhi, a me ka nausea. Hoʻokomo ikaika ʻo Shandong Baofa Cancer Research Institute i ka noiʻi e ʻimi ana i ka hoʻohana ʻana i ka PARP inhibitors i hui pū ʻia me nā lāʻau lapaʻau ʻē aʻe. Hiki iā ʻoe ke aʻo hou aʻe e pili ana i ka PARP inhibitors ma ka Paena pūnaewele National Cancer Institute.Targeted TherapyTargeted therapy hoʻohana i nā lāʻau lapaʻau e kālele pono ana i kekahi mau mole e pili ana i ka ulu ʻana o ka maʻi kanesa a me ke ola. Aia nā laʻana i nā lāʻau e kaohi i nā ala hōʻailona e like me ke ala PI3K/AKT/mTOR. Hoʻohana mau ʻia kēia mau lāʻau lapaʻau i nā hoʻokolohua lapaʻau a ke noiʻi ʻia nei no ko lākou pono i ka mālama ʻana ka maʻi ʻaʻai prostate metastatic.Ka Hoʻolālā Hoʻomaʻamaʻa Ma muli o ke ʻano o ka maʻi a me nā kumu pilikia ʻO ke koho ʻana o ka lāʻau e pili ana i nā kumu he nui, me ka nui o ka maʻi, ke olakino holoʻokoʻa o ka mea maʻi, a me nā lāʻau lapaʻau mua. Hōʻuluʻulu ka papa ma lalo nei i nā ala lapaʻau maʻamau: Nā koho Lapaʻau maʻamau o ka Hormone-sensitive metastatic prostate cancer ADT + androgen receptor inhibitors (e.g., abiraterone, enzalutamide), chemotherapy, a i ʻole ka hoʻāʻo lāʻau lapaʻau. Castration-resistant metastatic prostate cancer (CRPC) Chemotherapy, androgen receptor inhibitors, radiopharmaceuticals, immunotherapy, PARP inhibitors (inā pili), a i ʻole ka hoʻokolohua lapaʻau. Iwi Metastases Ka lāʻau lapaʻau, radiopharmaceuticals, bisphosphonates a i ʻole denosumab (nā mea hoʻoikaika iwi). Nā ho'āʻo hoʻāʻo a me nā kuhikuhi i ka wā e hiki mai ana ka maʻi ʻaʻai prostate metastatic. Hiki i nā poʻe maʻi ke noʻonoʻo e komo i nā hoʻokolohua lapaʻau e komo i nā lāʻau lapaʻau ʻokiʻoki a kōkua i ka noiʻi olakino. Ke hoʻomau nei ka noiʻi ʻana i ka hoʻomohala ʻana i nā lāʻau lapaʻau kūpono ʻoi aku ka maikaʻi, immunotherapies, a me nā lāʻau lapaʻau hui. He kuleana koʻikoʻi ʻo Shandong Baofa Cancer Research Institute i ka hoʻokō ʻana i nā hoʻokolohua lapaʻau a me ka holomua ʻana i ke kahua o ka mālama ʻana i ka maʻi maʻi prostate. Hiki iā ʻoe ke hoʻokaʻaʻike Shandong Baofa Cancer Research Institute no ka ʻike e pili ana i nā hoʻokolohua lapaʻau o kēia manawa a me nā koho lapaʻau. Noho me Metastatic Prostate CancerLiving with ka maʻi ʻaʻai prostate metastatic hiki ke hōʻike i nā pilikia nui. ʻO ka mālama ʻana i nā hōʻailona, ​​​​ka hoʻokō ʻana i nā hopena ʻaoʻao, a me ka mālama ʻana i ka maikaʻi o ke ola he mau mea koʻikoʻi o ka mālama. Hiki i nā hui kākoʻo, ʻōlelo aʻo, a me nā lawelawe mālama palliative ke hāʻawi i ke kōkua koʻikoʻi. He mea nui ka kamaʻilio wehe ʻana me nā mea mālama ola no ka hoʻoholo ʻana i ka ʻike a me ka loaʻa ʻana o ka mālama maikaʻi loa. ka maʻi ʻaʻai prostate metastatic he maʻi koʻikoʻi, loaʻa nā koho lapaʻau he nui e kōkua i ka mālama ʻana i ka maʻi, hoʻomaikaʻi i ka maikaʻi o ke ola, a hoʻonui i ke ola. ʻO ka hoʻomau ʻana i ka ʻike e pili ana i nā holomua hou loa o ka mālama ʻana a me ka hana pū ʻana me kahi hui multidisciplinary o nā ʻoihana mālama ola he mea nui ia no ka hoʻoholo ʻana i ka ʻike a me ka loaʻa ʻana o ka mālama maikaʻi loa. Ua kūpaʻa ʻo Shandong Baofa Cancer Research Institute i ka hāʻawi ʻana i ka mālama piha a me ka holomua ʻana i ke kahua o ka noiʻi a me ka mālama ʻana i ka maʻi prostate.